ACLX Live signals | Maximize Profits with Getagraph.com

SELL 103976 min ago

@ $63.29

Issued: 14 Feb 2024 @ 09:30

Return: -18.02%

Previous signal: Feb 12 - 13:39

Previous signal: Buy

Return: -0.81 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:26):

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases...

Stats
Today's Volume	200 403
Average Volume	461 195
Market Cap	2.74B
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.510 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-35.29
ATR14	$0.0550 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Ware Olivia C	Sell	9 402	Stock Option (right to buy)
2024-04-16	Ware Olivia C	Buy	9 402	Common Stock
2024-04-16	Ware Olivia C	Sell	6 790	Common Stock
2024-04-16	Ware Olivia C	Sell	2 612	Common Stock
2024-04-01	Elghandour Rami	Sell	14 919	Common Stock

INSIDER POWER
-47.12
Last 100 transactions
Buy: 1 139 480 \| Sell: 3 755 187

Volume Correlation

Long: -0.10 (neutral)

Short: -0.53 (weak negative)

Signal:(33.46) Neutral

Arcellx, Inc. Correlation

10 Most Positive Correlations
RMRM	0.953
MOTNU	0.932
LIAN	0.911
NYMX	0.911
SDIG	0.909
AGYS	0.909
GLMD	0.908
PSCH	0.908
ICON	0.906
PSCC	0.906

10 Most Negative Correlations
ATHN	-0.935
NXTC	-0.932
PTRA	-0.932
IOAC	-0.932
LITE	-0.93
GTLB	-0.928
CWBR	-0.924
AXDX	-0.921
TSLA	-0.92
LGHL	-0.917

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arcellx, Inc. Correlation - Currency/Commodity

0.09
( neutral )

0.27
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.17
( neutral )

0.15
( neutral )

Arcellx, Inc. Financials

Annual	2023
Revenue:	$110.32M
Gross Profit:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2023
Revenue:	$110.32M
Gross Profit:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2022
Revenue:	$0
Gross Profit:	$-2.22M (0.00 %)
EPS:	$-4.22

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-6.02

Financial Reports:

No articles found.

Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.